Forecast

Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)

From	National Institutes of Health
Who can apply	state governments, counties, cities and townships, special districts (water, fire, parks, etc.), school districts, public colleges and universities and 9 more types
Eligibility notes	Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;
How much	Amount not stated
Deadline	Fri, Jun 18, 2027 (estimated) (237 days left)
Category	Health
Type	Cooperative agreement
Opportunity #	RFA-AG-28-009
Assistance listing	93.866
Posted	Thu, Aug 13, 2026

Heads-up: Forecast: not open yet. Dates and amounts are the agency's estimates.

Open the official posting

From the notice

The National Institute on Aging (NIA) intends to publish a Notice of Funding Opportunity (NOFO) to solicit applications that propose pre-clinical and early-stage clinical (Phase I) development of novel small-molecule and biologic drug candidates that aim to prevent Alzheimer's disease (AD), slow its progression, or treat its cognitive and behavioral symptoms.Through the NOFO, NIA is continuing the Alzheimer's Drug-Development Program (ADDP) with the aim of catalyzing drug development for AD. The ADDP is designed to provide funding support to academic and biotech researchers for preclinical drug development activities that can be conducted in their own laboratories or conducted in collaboration with contract research organizations that specialize in preclinical drug development activities. By supporting the most challenging and costly steps of drug development and seamlessly connecting preclinical drug development and first-in-human testing for drug candidates, the ADDP program seeks to: Continue to expand the number of investigational new drug candidates for a portfolio of emerging therapeutic targets; Continue to expand the therapeutic pipeline for AD with drug candidates targeting multiple underlying disease mechanisms that can be used as mono-therapy or as part of combination therapy; and Enable a precision medicine approach to AD drug development. The NOFO will utilize the U01 activity code. Applications are not being solicited at this time. This notice is being provided

We may have shortened this. The official posting is the record. We are not affiliated with the agency that published it.